Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
The global Inhaled Nitric Oxide market size was valued at US$ 1216 million in 2023 and is forecast to a readjusted size of USD 2086 million by 2030 with a CAGR of 8.1% during review period.
Mallinckrodt monopolizes the global Inhaled Nitric Oxide market, holding a share about 65%.
North America is the largest market, with a share about 77%, followed by Asia-Pacific and Europe, have a share about 20 percent.
In terms of product, 800 ppm is the largest segment, with a share over 50%. And in terms of application, the largest application is Near-term and Pre-term Infants PPHN, followed by Children and Adult ARDS, etc.
This report is a detailed and comprehensive analysis for global Inhaled Nitric Oxide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Inhaled Nitric Oxide market size and forecasts, in consumption value ($ Million), sales quantity (M L), and average selling prices (US$/L), 2019-2030
Global Inhaled Nitric Oxide market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M L), and average selling prices (US$/L), 2019-2030
Global Inhaled Nitric Oxide market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M L), and average selling prices (US$/L), 2019-2030
Global Inhaled Nitric Oxide market shares of main players, shipments in revenue ($ Million), sales quantity (M L), and ASP (US$/L), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Inhaled Nitric Oxide
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Inhaled Nitric Oxide market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Mallinckrodt, Praxair (Linde plc), Air Liquide, BOC Healthcare (Linde Group), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Inhaled Nitric Oxide market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
800 ppm
100 ppm
Others
麻豆原创 segment by Application
Near-term and Pre-term Infants PPHN
Children and Adult ARDS
Other Diseases
Major players covered
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Inhaled Nitric Oxide product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Inhaled Nitric Oxide, with price, sales quantity, revenue, and global market share of Inhaled Nitric Oxide from 2019 to 2024.
Chapter 3, the Inhaled Nitric Oxide competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Inhaled Nitric Oxide breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Inhaled Nitric Oxide market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Inhaled Nitric Oxide.
Chapter 14 and 15, to describe Inhaled Nitric Oxide sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Inhaled Nitric Oxide Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 800 ppm
1.3.3 100 ppm
1.3.4 Others
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Inhaled Nitric Oxide Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Near-term and Pre-term Infants PPHN
1.4.3 Children and Adult ARDS
1.4.4 Other Diseases
1.5 Global Inhaled Nitric Oxide 麻豆原创 Size & Forecast
1.5.1 Global Inhaled Nitric Oxide Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Inhaled Nitric Oxide Sales Quantity (2019-2030)
1.5.3 Global Inhaled Nitric Oxide Average Price (2019-2030)
2 Manufacturers Profiles
2.1 Mallinckrodt
2.1.1 Mallinckrodt Details
2.1.2 Mallinckrodt Major Business
2.1.3 Mallinckrodt Inhaled Nitric Oxide Product and Services
2.1.4 Mallinckrodt Inhaled Nitric Oxide Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Mallinckrodt Recent Developments/Updates
2.2 Praxair (Linde plc)
2.2.1 Praxair (Linde plc) Details
2.2.2 Praxair (Linde plc) Major Business
2.2.3 Praxair (Linde plc) Inhaled Nitric Oxide Product and Services
2.2.4 Praxair (Linde plc) Inhaled Nitric Oxide Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Praxair (Linde plc) Recent Developments/Updates
2.3 Air Liquide
2.3.1 Air Liquide Details
2.3.2 Air Liquide Major Business
2.3.3 Air Liquide Inhaled Nitric Oxide Product and Services
2.3.4 Air Liquide Inhaled Nitric Oxide Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Air Liquide Recent Developments/Updates
2.4 BOC Healthcare (Linde Group)
2.4.1 BOC Healthcare (Linde Group) Details
2.4.2 BOC Healthcare (Linde Group) Major Business
2.4.3 BOC Healthcare (Linde Group) Inhaled Nitric Oxide Product and Services
2.4.4 BOC Healthcare (Linde Group) Inhaled Nitric Oxide Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 BOC Healthcare (Linde Group) Recent Developments/Updates
3 Competitive Environment: Inhaled Nitric Oxide by Manufacturer
3.1 Global Inhaled Nitric Oxide Sales Quantity by Manufacturer (2019-2024)
3.2 Global Inhaled Nitric Oxide Revenue by Manufacturer (2019-2024)
3.3 Global Inhaled Nitric Oxide Average Price by Manufacturer (2019-2024)
3.4 麻豆原创 Share Analysis (2023)
3.4.1 Producer Shipments of Inhaled Nitric Oxide by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2023
3.4.2 Top 3 Inhaled Nitric Oxide Manufacturer 麻豆原创 Share in 2023
3.4.3 Top 6 Inhaled Nitric Oxide Manufacturer 麻豆原创 Share in 2023
3.5 Inhaled Nitric Oxide 麻豆原创: Overall Company Footprint Analysis
3.5.1 Inhaled Nitric Oxide 麻豆原创: Region Footprint
3.5.2 Inhaled Nitric Oxide 麻豆原创: Company Product Type Footprint
3.5.3 Inhaled Nitric Oxide 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Inhaled Nitric Oxide 麻豆原创 Size by Region
4.1.1 Global Inhaled Nitric Oxide Sales Quantity by Region (2019-2030)
4.1.2 Global Inhaled Nitric Oxide Consumption Value by Region (2019-2030)
4.1.3 Global Inhaled Nitric Oxide Average Price by Region (2019-2030)
4.2 North America Inhaled Nitric Oxide Consumption Value (2019-2030)
4.3 Europe Inhaled Nitric Oxide Consumption Value (2019-2030)
4.4 Asia-Pacific Inhaled Nitric Oxide Consumption Value (2019-2030)
4.5 South America Inhaled Nitric Oxide Consumption Value (2019-2030)
4.6 Middle East & Africa Inhaled Nitric Oxide Consumption Value (2019-2030)
5 麻豆原创 Segment by Type
5.1 Global Inhaled Nitric Oxide Sales Quantity by Type (2019-2030)
5.2 Global Inhaled Nitric Oxide Consumption Value by Type (2019-2030)
5.3 Global Inhaled Nitric Oxide Average Price by Type (2019-2030)
6 麻豆原创 Segment by Application
6.1 Global Inhaled Nitric Oxide Sales Quantity by Application (2019-2030)
6.2 Global Inhaled Nitric Oxide Consumption Value by Application (2019-2030)
6.3 Global Inhaled Nitric Oxide Average Price by Application (2019-2030)
7 North America
7.1 North America Inhaled Nitric Oxide Sales Quantity by Type (2019-2030)
7.2 North America Inhaled Nitric Oxide Sales Quantity by Application (2019-2030)
7.3 North America Inhaled Nitric Oxide 麻豆原创 Size by Country
7.3.1 North America Inhaled Nitric Oxide Sales Quantity by Country (2019-2030)
7.3.2 North America Inhaled Nitric Oxide Consumption Value by Country (2019-2030)
7.3.3 United States 麻豆原创 Size and Forecast (2019-2030)
7.3.4 Canada 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Mexico 麻豆原创 Size and Forecast (2019-2030)
8 Europe
8.1 Europe Inhaled Nitric Oxide Sales Quantity by Type (2019-2030)
8.2 Europe Inhaled Nitric Oxide Sales Quantity by Application (2019-2030)
8.3 Europe Inhaled Nitric Oxide 麻豆原创 Size by Country
8.3.1 Europe Inhaled Nitric Oxide Sales Quantity by Country (2019-2030)
8.3.2 Europe Inhaled Nitric Oxide Consumption Value by Country (2019-2030)
8.3.3 Germany 麻豆原创 Size and Forecast (2019-2030)
8.3.4 France 麻豆原创 Size and Forecast (2019-2030)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Russia 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Italy 麻豆原创 Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific Inhaled Nitric Oxide Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Inhaled Nitric Oxide Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Inhaled Nitric Oxide 麻豆原创 Size by Region
9.3.1 Asia-Pacific Inhaled Nitric Oxide Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Inhaled Nitric Oxide Consumption Value by Region (2019-2030)
9.3.3 China 麻豆原创 Size and Forecast (2019-2030)
9.3.4 Japan 麻豆原创 Size and Forecast (2019-2030)
9.3.5 South Korea 麻豆原创 Size and Forecast (2019-2030)
9.3.6 India 麻豆原创 Size and Forecast (2019-2030)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2019-2030)
9.3.8 Australia 麻豆原创 Size and Forecast (2019-2030)
10 South America
10.1 South America Inhaled Nitric Oxide Sales Quantity by Type (2019-2030)
10.2 South America Inhaled Nitric Oxide Sales Quantity by Application (2019-2030)
10.3 South America Inhaled Nitric Oxide 麻豆原创 Size by Country
10.3.1 South America Inhaled Nitric Oxide Sales Quantity by Country (2019-2030)
10.3.2 South America Inhaled Nitric Oxide Consumption Value by Country (2019-2030)
10.3.3 Brazil 麻豆原创 Size and Forecast (2019-2030)
10.3.4 Argentina 麻豆原创 Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa Inhaled Nitric Oxide Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Inhaled Nitric Oxide Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Inhaled Nitric Oxide 麻豆原创 Size by Country
11.3.1 Middle East & Africa Inhaled Nitric Oxide Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Inhaled Nitric Oxide Consumption Value by Country (2019-2030)
11.3.3 Turkey 麻豆原创 Size and Forecast (2019-2030)
11.3.4 Egypt 麻豆原创 Size and Forecast (2019-2030)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2019-2030)
11.3.6 South Africa 麻豆原创 Size and Forecast (2019-2030)
12 麻豆原创 Dynamics
12.1 Inhaled Nitric Oxide 麻豆原创 Drivers
12.2 Inhaled Nitric Oxide 麻豆原创 Restraints
12.3 Inhaled Nitric Oxide Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Inhaled Nitric Oxide and Key Manufacturers
13.2 Manufacturing Costs Percentage of Inhaled Nitric Oxide
13.3 Inhaled Nitric Oxide Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Inhaled Nitric Oxide Typical Distributors
14.3 Inhaled Nitric Oxide Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
听
听
*If Applicable.
